The market disc, basket and decanter centrifuges for the pharmaceutical industry will rise worldwide to over $200 million in 2004. This is a smaller market segment than wastewater and chemical, but it is growing at an impressive 8 percent per year. The McIlvaine Company forecasts all the sedimentation and centrifugation markets in its online market report. It also has a directory with key decision-makers and a database of projects. Several of the pharmaceutical projects with start-ups in 2004 are described below. We are also including several of the articles appearing in the most recent updates of the market report.
For more information on Sedimentation/Centrifguation: World Markets click on http://www.mcilvainecompany.com/water.html#n005 .
For more information on U.S. Cleanrooms and People click on http://www.mcilvainecompany.com/cleanroom.html#US .
For more information World Cleanroom Projects click on http://www.mcilvainecompany.com/cleanroom.html#80A .
Revision Date: 8/1/2003
Entry Date: 8/1/2003
Startup Date: 1991
Expansion Date: 2003
Country: Puerto Rico
City: Arecibo or Barcelooneta
Size: existing Class 10,000 Cleanroom
Product: biotechnology and pharmaceuticals
Address:
Telephone:
SIC Description: Biotechnology
Description:
Merck Sharpe & Dohme will expand its operation in Puerto Rico by constructing a $300 million biotechnology plant. It is still unclear if the plant will be in Arecibo or Barceloneta, where Merck currently has facilities, or at a different site.
|
Contractors |
Contractor Comment |
|
Halco Products |
CR builder |
Project Title: Boehringer Ingelheim
Revision Date: 6/1/2003
Entry Date: 6/1/2003
Startup Date: 2004
Expansion Date:
Country: Austria
City: Vienna
Size:
Product: biopharmaceuticals
Address:
Telephone:
SIC Description: Pharmaceuticals
Description:
M+W Zander will engineer and coordinate the construction of a new
biopharmaceutical facility in Vienna for Boehringer Ingelheim Austria. The
facility will produce biopharmaceutical active agents
Project Title: Shire
Revision Date: 5/1/2003
Entry Date: 6/1/2003
Startup Date: 2004
Expansion Date:
Country: Canada
City: Laval
Size:
Product: pharmaceuticals and biotechnology
Address:
Telephone: 44-1256-894-280
SIC Description: Pharmaceuticals
Description:
Shire Pharmaceuticals will invest CDN $28 million in the construction
of a new global vaccine research center. The Centre will support the company's
biologics business and will be located at Shire's current site in Laval.
Completion is planned for 2004.
Project Title: Cytovance Biologics
Revision Date: 7/1/2003
Entry Date: 7/1/2003
Startup Date: 2004
Expansion Date: 2003
Country: OK
City: Oklahoma City
Size: 26,000 sq. ft. plant
Product: biotechnology
Address:
Telephone:
SIC Description: Biotechnology
Description:
Cytovance Biologics is building a $12 million bio-pharm plant. The
company will employ 40-60 people, including biologists and microbiologists,
technical specialists and a quality assurance team. Cytovance plans to spend $2
million to equip the 26,000 sq. ft. plant expected to open by late 2004.
Cytovance will produce a new generation of medicines that use natural protein
bases as a way to treat cancer, diabetes and heart disease. The plant will
provide testing trials for drugs developed by other companies in Oklahoma City's
Presbyterian Health Foundation Research Park.
Project Title: Omega Protein
Revision Date: 9/1/2003
Entry Date: 9/1/2003
Startup Date: 2004
Expansion Date:
Country: VA
City: Reedville
Size: 60,000 sq. ft. facility
Product: vitamins and food supplements
Address:
Telephone:
SIC Description: Pharmaceuticals
Description:
Suitt Construction, a BE&K subsidiary, has been awarded a contract to
build a $16 million processing facility for Omega Protein, the nation's largest
manufacturer of heart-healthy fish oils for human consumption. The 60,000 sq.
ft. facility will include 7,000 sq. ft. of office and laboratory space as well
as 20,000 sq. ft. dedicated to dry and freeze space. The scope of the work
encompasses a separate mechanical building to house boilers, air compressors,
cooling towers and equipment for chilled water and wastewater pretreatment. The
projected completion date for construction is May 2004.
China's pharmaceutical industry will grow by leaps and bounds in five years and will become the fifth largest pharmaceutical market in the world by 2010, according to a forecast on the development of the global medical industry made at the fourth Asian Pacific Regional Pharmaceutical Industrial Round-Table Conference held August 2003 in Shanghai.
According to presidents of pharmaceutical enterprises and medical scholars at the conference, Europe and the United States currently have the lead in the development of the pharmaceutical industry but with the improvement of Asia's productivity, expansion of its research and development and increase in consumption, the continent's industry will soon catch up. Over the past two decades, income from prescription drugs worldwide has risen 10 percent annually, with growth in Asia topping the list and China in a prime position.
Statistics show that China is the seventh-largest pharmaceutical market in the world worth US$6.8 billion in 2000. Although this figure is still behind the United States, the world's largest market worth US$150 billion, and Japan, the second largest with at US$58 billion, China has huge potential. One reason is the annual rise of 8 percent of the aging population in North Asia, especially in China. By the end of 2020, the number of people aged over 65 years old will account for 16 percent of China's population. The second is that China's birth rate has continuously declined, currently standing at 1.8 percent - if a birth rate stands at below 2 percent, a graying population will be an obvious feature. The third reason is that the life expectancy of the Chinese averages 70 years, similar to that of Americans. With the increase of China's per capita GDP, the social purchasing power will expand, enabling the pharmaceutical market to go up 6-8 percent annually. China's pharmaceutical sales will reach US$14 billion by the end of 2005, and US$24 billion by 2010, becoming the fifth largest market in the world after the United States, Japan, Germany, and France.
The UK pharmaceutical industry employs approximately 60,000 people - a third of whom are directly involved in research and development - and is fifth largest in the world by total sales (7 percent of world sales) after the USA, Japan, Germany and France. It is also the UK's third biggest earner by trade surplus (£2,300 million in 1997) after North Sea Oil and power generation equipment. Although the UK itself represents only 3 percent of the world market; the UK is the third largest direct exporter of pharmaceuticals; has the third largest world trade surplus; and accounts for 10 percent of world pharmaceutical R&D expenditure. In 1997, 'medicinal and pharmaceutical products' was the UK's eleventh largest exporting sector, with exports of £5,500 million. Five of the world's top 20 best-selling drugs were developed in British labs.
Bob McIlvaine
847-784-0012